论文部分内容阅读
全身性化疗对转移的小细胞肺癌病人是良好的处理。许多化疗药物对小细胞肺癌具有活性,联合应用的有效率可达80%。有效率虽高,但仅有5～15%的病人存活5年以上,具广泛性疾病的患者治愈者极为罕见。碳铂(carboplastin,CBDCA)是第二代铂类物,由于它没有肾毒性,故受临床重视。Smith等人报道过56例小细胞肺癌病人用碳铂的总有效率为41%;30例未曾治疗的Ⅱ期小细胞肺癌病人有效率为60%。本研究的目的是评价碳铂对未经治疗的广泛转移的小细胞肺癌病人的活性。病人与方法:自1984年8月至1985年12月,对未经
Systemic chemotherapy is a good treatment for patients with metastatic SCLC. Many chemotherapeutic drugs are active against small cell lung cancer, and the combined efficacy is up to 80%. Although the efficiency is high, only 5 to 15% of patients survive for more than 5 years. Patients with extensive disease are extremely rare. Carboplastin (CBDCA) is a second-generation platinum compound, which is of clinical importance because it has no nephrotoxicity. Smith et al. reported that the total effective rate of carboplatin in 56 patients with small cell lung cancer was 41%; the effective rate of 30 untreated patients with stage II small cell lung cancer was 60%. The purpose of this study was to evaluate the activity of carboplatin in untreated patients with extensive metastatic SCLC. Patients and methods: From August 1984 to December 1985,